Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
21 nov 2006 - 17:39
Statutaire naam
Crucell N.V.
Titel
Crucell Equity Offering Priced at € 17.50 per Share; € 80 Million Raised
Bericht
Leiden, The Netherlands, November 21, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) has placed 4,571,429 new ordinary shares at a price of € 17.50 per share. The company raised gross proceeds of € 80 million. ABN AMRO Rothschild acted as Sole Global Coordinator and Sole Bookrunner of the transaction.
Payment for and delivery of the new shares is expected to take place on November 24, 2006, at which expected date the new shares will be admitted to trading and listing on Eurolist by Euronext Amsterdam. After closing of the offering, Crucell will have 63,884,329 ordinary shares outstanding.
This press release is not an offer of securities for sale in the United States. The offer and sale of the new ordinary shares has not been, nor will it be, registered under the United States Securities Act of 1933 and the new ordinary shares may not be offered or sold in the United States in the absence of such registration or an exemption from registration.
About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell’s core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiari
Datum laatste update: 01 september 2024